INDIVIDUALIZATION OF TREATMENT IN BENIGN PROSTATIC HYPERPLASIA

The management of benign prostatic hyperplasia (BPH) is under constant review and discussion. Research leads to a better understanding of th e disease, new therapies become available and treatment guidelines are revised accordingly. One of the most striking trends in the managemen t of BPH is the move from surgical to medical treatment. Pharmacologic al regimes are now a valid option for many men with BPH. Of these, alp ha-blockers are emerging as the preferred agents, with demonstrable ef ficacy and tolerability in controlled clinical studies, offering rapid relief of BPH symptoms.